Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to “Hold” at Wall Street Zen

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

A number of other analysts have also issued reports on the company. HC Wainwright boosted their price objective on Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Leerink Partners raised their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Bank of America lifted their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. JPMorgan Chase & Co. upped their price target on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Finally, Truist Financial increased their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $40.67.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $27.86 on Friday. The company has a market cap of $1.63 billion, a P/E ratio of -3.92 and a beta of 0.89. The stock’s fifty day moving average price is $28.17 and its two-hundred day moving average price is $32.54. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,932 shares of the stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the insider owned 29,190 shares of the company’s stock, valued at $790,757.10. This represents a 9.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Cecilia Jones sold 2,932 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the sale, the chief financial officer owned 37,394 shares in the company, valued at $1,013,003.46. The trade was a 7.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 36,262 shares of company stock worth $984,237. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. raised its holdings in shares of Agios Pharmaceuticals by 31.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 21,071 shares of the biopharmaceutical company’s stock valued at $574,000 after buying an additional 5,033 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $183,000. Seven Fleet Capital Management LP bought a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $864,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $25,000. Finally, Invesco Ltd. raised its stake in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock worth $3,881,000 after acquiring an additional 15,604 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.